Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.35 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.35 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLG | P54098 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065468 | 0.86 | POLA1 (0.34) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL2885970 | 0.85 | ABL1 (0.30) | — | |
| SCHEMBL25416263 | 0.79 | PDE3A (0.43) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL2064246 | 0.79 | ABL1 (0.31) | — | |
| SCHEMBL2889203 | 0.79 | PDE3A (0.38) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL2889219 | 0.79 | PDE3A (0.36) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL16493643 | 0.73 | POLA1 (0.35) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL2064812 | 0.72 | PDE3A (0.36) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL16493927 | 0.72 | PDE3A (0.34) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL25416162 | 0.71 | LMNA (0.39) | PDE3APDE4DSLC29A1LMNACACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022468-A1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK SHARP & DOHME LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022468-A1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | RNGTT, NSUN2, RNASE1 | PDE3A 484/4885PDE4D 368/4885SLC29A1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.